NCT04317040View on ClinicalTrials.gov

Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)

PHASE3CompletedINTERVENTIONAL
Enrollment

234

Participants

Timeline

Start Date

April 24, 2020

Primary Completion Date

October 20, 2020

Study Completion Date

October 20, 2020

Conditions
Coronavirus Disease 2019 (COVID-19)
Interventions
DRUG

Efprezimod alfa

Efprezimod alfa is given on Day 1.

DRUG

Placebo

Placebo is given on Day 1.

Trial Locations (10)

20850

Shady Grove Medical Center, Rockville

20904

White Oak Medical Center, Silver Spring

21201

Institute of Human Virology, University of Maryland Baltimore, Baltimore

21401

Anne Anundel Medical Center, Annapolis

32207

Baptist Health Research Institute, Jacksonville

43210

The Ohio State University Medical Center, Columbus

44106

University Hospitals of Cleveland, Cleveland

77030

University of Texas at Houston, Houston

08103

Cooper University Hospital, Camden

07960

Atlantic Health System, Morristown

All Listed Sponsors
lead

Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT04317040 - Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007) | Biotech Hunter | Biotech Hunter